Tapering cuts risk for overdose among those with opioid use disorder
THURSDAY, Dec. 8, 2022 (HealthDay News) — Discontinuing prescribed opioids in people with chronic pain is associated with increased overdose risk, according to a study published online Dec. 1 in PLOS Medicine.
Mary Clare Kennedy, Ph.D., from the University of British Columbia-Okanagan in Kelowna, Canada, and colleagues used a 20 percent random sample of residents in the provincial health insurance client roster to identify 14,037 persons aged 14 to 74 years on long-term opioid therapy for pain (≥90 days).
The researchers found that during a median 3.7 years of follow-up, discontinuing opioids (at least seven-day gap[s] in therapy) was associated with increased overdose risk among people without opioid use disorder (OUD; adjusted hazard ratio [aHR], 1.44), people with OUD not receiving opioid agonist therapy (OAT; aHR, 3.18), and people with OUD receiving OAT (aHR, 2.52), after adjusting for a range of demographic, prescription, comorbidity, and social-structural exposures. Among people with OUD not receiving OAT, opioid tapering (two or more sequential decreases of ≥5 percent in average daily morphine milligram equivalents) was associated with decreased overdose risk (aHR, 0.31).
“These findings point to the need to avoid abrupt discontinuation of opioid treatment for pain and to enhance guidance for prescribers in modifying opioid treatment tapering strategies on the basis of OUD and OAT status,” the authors write.
Ultrasound-Guided Hydrodissection Yields Improvements in Carpal Tunnel
Withdrawal From Medetomidine Increasingly Seen in ICUs
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis